Institutional Research
The LifeTech Capital research team are recognized authorities on
oncology drugs, stem cells, infectious diseases, neurological disorders,
metabolic disorders, gene therapy, drug delivery, cardiovascular and
orthopedic therapeutics and devices. Their expertise is often sought by
CEOs and Board of Directors.
Our research helps provide clients with the
confidence to make rational investment decisions in the complex
fast-moving biotechnology, medtech and lifetech (air-food-water)
industries.
CLICK HERE to Access our
Current Research Reports
Institutional Research Team
Stephen M. Dunn
President LifeTech Capital
& Senior
Managing Director of Research
SDunn@LifeTechCapital.com
Mr. Dunn was previously the Managing Director of Life Sciences Research at
Jesup & Lamont, as well as Director of Research for Dawson James Securities
and Director of Life Sciences at Cabot Adams venture capital group.
He has also held management positions in Business Development, Finance and
Operations having worked in over 25 countries in North America, Europe and
the Far East with biomedical companies including Beckman Coulter, Coulter,
Cordis (Johnson & Johnson), Telectronics (St. Jude Medical) as well as
several smaller companies. With over 25 years within the global biomedical
industry, Mr. Dunn has negotiated numerous intellectual property licenses,
product development agreements, venture funding, M&A and joint ventures with
companies such as GlaxoSmithKline, Pharmacia, Novartis, Bayer, Schering AG,
Wyeth, Eli Lilly, Pfizer, Genzyme, Martek Biosciences, Fisher Life Sciences,
Becton Dickinson, Idec Pharmaceuticals, Ortho Diagnostics, DakoCytomation,
Los Alamos and Sandia National Laboratories, the Mayo Clinic Foundation and
the Dana-Farber Institute along with dozens of smaller public and private
companies throughout the world.
Mr. Dunn is a 5-star biotechnology analyst on StarMine and has appeared in
both the financial and scientific media such as The Wall Street Journal,
CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The
Scientist, BioWorld and many other media outlets. He is also a frequent
speaker and panel member for many financial, medical and venture capital
events.
William D. Dawson
Senior
Vice President of Research
WDawson@LifeTechCapital.com
William “Bill” Dawson was previously
Senior
Vice President of Life Sciences Research at Jesup & Lamont and a biotechnology analyst at Dawson James
Securities where he assisted in the preparation of institutional research
reports covering the small cap life sciences industry. Prior becoming a
research analyst, Mr. Dawson was a capital markets representative with
Dawson James where he assisted in the successful marketing of numerous
banking transactions including private placements, registered secondary’s,
and initial public offerings and conducted deal and non-deal road shows for
biotechnology companies in the U.S.
Mr. Dawson has appeared as a correspondent for OneMedTV where he interviews
senior management of emerging biotechnology, healthcare and medical device
companies. Mr. Dawson holds Bachelor Degrees in Biochemistry and Business
Management from Eckerd College in St. Petersburg FL where he acted as
Treasurer of the American Chemical Society for the Eckerd College chapter.